Skip to main content
SpringerLink
Log in
Book cover

Viruses and Human Cancer pp 113–133Cite as

Prevention of Hepatitis C Virus Infection and Liver Cancer

  • Chapter
  • First Online:

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 193))

Abstract

Hepatocellular carcinoma (HCC) is the fifth most prevalent cancer and the third leading cause of cancer-related death, and its incidence is increasing. The majority of HCC cases are associated with chronic viral hepatitis. With over 170 million individuals chronically infected with hepatitis C virus (HCV) worldwide, HCV is currently a serious global health concern, leading to chronic hepatitis, cirrhosis and HCC, thereby causing significant morbidity and mortality. With the incidence of HCV infection increasing, the problem of HCV-associated HCC is expected to worsen as well, with the majority of HCCs developing in the setting of cirrhosis. Thus, it is imperative to provide antiviral therapy to infected individuals prior to the development of established cirrhosis in order to reduce the risk of subsequent HCC. Indeed, the successful eradication of HCV is associated with clinical and histological improvement as well as a greatly reduced risk of subsequent HCC development. Even after the development of cirrhosis, successful viral clearance is still associated with reduced HCC risk. Current standard of care antiviral treatment consists of pegylated interferon-α and ribavirin, but viral clearance rates are suboptimal with this regimen, especially in difficult to treat cohorts. However, there is a myriad of different classes of HCV-specific direct-acting antiviral agents currently in development, which can be used in combination with one another or with standard of care treatment to improve HCV cure rates. Preventative and therapeutic vaccines against HCV remain an area of ongoing research with good progress towards developing an effective vaccine in the future.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • National institutes of health consensus development conference statement: Management of hepatitis c (2002) (June 10–12, 2002). Gastroenterology, 123(6), 2082–2099

    Google Scholar 

  • Alter MJ (1995) Epidemiology of hepatitis c in the west. Semin Liver Dis 15(1):5–14

    Article  PubMed  CAS  Google Scholar 

  • Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R, Investigators HR (2011) Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 364(13):1207–1217

    Article  PubMed  CAS  Google Scholar 

  • Bartenschlager R, Penin F, Lohmann V, Andre P (2011) Assembly of infectious hepatitis c virus particles. Trends Microbiol 19(2):95–103

    Article  PubMed  CAS  Google Scholar 

  • Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayon M, Cordoba J, Herola A, Ascher N, Mir J, Berenguer J, Wright TL (2000) HCV-related fibrosis progression following liver transplantation: Increase in recent years. J Hepatol 32(4):673–684

    Article  PubMed  CAS  Google Scholar 

  • Brainard DM, Petry A, Van Dyck K, Nachbar RB, De Lepeleire IM, Caro L, Stone JA, Sun P, Uhle M, Wagner FD, O’mara E, Wagner JA (2010) Safety and antiviral activity of MK-5172, a novel HCV N53/4a protease inhibitor with potent activity against known resistance mutants, in genotype 1 and 3 HCV-infected patients. Hepatology 52(4):706A–707A

    Google Scholar 

  • Bressler BL, Guindi M, Tomlinson G, Heathcote J (2003) High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis c. Hepatology (Baltimore, Md.), vol 38(3) pp 639–44

    Google Scholar 

  • Bruix J, Sherman M, Practice Guidelines Committee A, A. F. T. S. O. L. D. (2005) Management of hepatocellular carcinoma. Hepatology (Baltimore, Md.) 42(5), 1208–1236

    Google Scholar 

  • Bruno S, Stroffolini T, Colombo M, Bollani S, Benvegno L, Mazzella G, Ascione A, Santantonio T, Piccinino F, Andreone P, Mangia A, Gaeta GB, Persico M, Fagiuoli S, Almasio PL, Italian Association of the Study of the Liver D (2007) Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: A retrospective study. Hepatology (Baltimore, Md.), 45(3), 579–587

    Google Scholar 

  • Buhler S, Bartenschlager R (2012) New targets for antiviral therapy of chronic hepatitis c. Liver international: official J Int Assoc Liver, 32 Suppl 1, pp 9–16

    Google Scholar 

  • Chayama K, Takahashi S, Toyota J, Karino Y, Ikeda K, Ishikawa H, Watanabe H, Mcphee F, Hughes E Kumada H (2012) Dual therapy with the nonstructural protein 5a inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis c virus genotype 1b-infected null responders. Hepatology (Baltimore, Md.) 55(3), 742–748

    Google Scholar 

  • Chen SL, Morgan TR (2006) The natural history of hepatitis c virus (HCV) infection. Int J Med Sci 3(2):47–52

    Article  PubMed  Google Scholar 

  • Chevaliez S, Pawlotsky J-M (2007) Hepatitis c virus: virology, diagnosis and management of antiviral therapy. World J Gastroenterology:WJG 13(17):2461–2466

    CAS  Google Scholar 

  • Cho LY, Yang JJ, Ko K-P, Park B, Shin A, Lim MK, Oh J-K, Park S, Kim YJ, Shin H-R, Yoo K-Y, Park SK (2011) Coinfection of hepatitis b and c viruses and risk of hepatocellular carcinoma: systematic review and meta-analysis. Int J Cancer J Int du Cancer 128(1):176–184

    Article  CAS  Google Scholar 

  • Crotty S, Cameron C, Andino R (2002) Ribavirin’s antiviral mechanism of action: Lethal mutagenesis? J Molecular Med-Jmm 80(2):86–95

    Article  CAS  Google Scholar 

  • Davis GL, Albright JE, Cook SF, Rosenberg DM (2003) Projecting future complications of chronic hepatitis c in the united states. Liver Transpl 9(4):331–338

    Article  PubMed  Google Scholar 

  • Di Martino V, Rufat P, Boyer N, Renard P, Degos F, Martinot-Peignoux M, Matheron S, Le Moing V, Vachon F, Degott C, Valla D, Marcellin P (2001) The influence of human immunodeficiency virus coinfection on chronic hepatitis c in injection drug users: A long-term retrospective cohort study. Hepatology (Baltimore, Md.) 34(6), 1193–1199

    Google Scholar 

  • Dibisceglie AM, Conjeevaram HS, Fried MW, Sallie R, Park Y, Yurdaydin C, Swain M, Kleiner DE, Mahaney K, Hoofnagle JH, Wright D (1995) Ribavirin as therapy for chronic hepatitis-c—a randomized, double-blind, placebo-controlled trial. Ann Intern Med 123(12), 897

    Google Scholar 

  • Donato F, Tagger A, Gelatti U, Parrinello G, Boffetta P, Albertini A, Decarli A, Trevisi P, Ribero ML, Martelli C, Porru S, Nardi G (2002) Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 155(4):323–331

    Article  PubMed  CAS  Google Scholar 

  • Dore GJ, Law M, Macdonald M, Kaldor JM (2003) Epidemiology of hepatitis c virus infection in Australia. J Clin Virol 26(2):171–184

    Article  PubMed  Google Scholar 

  • Drane D, Maraskovsky E, Gibson R, Mitchell S, Barnden M, Moskwa A, Shaw D, Gervase B, Coates S, Houghton M, Basser R (2009) Priming of CD4 + and CD8 + t cell responses using a HCV core ISCOMATRIX vaccine: a phase I study in healthy volunteers. Human vaccines 5(3):151–157

    Article  PubMed  CAS  Google Scholar 

  • El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132(7):2557–2576

    Article  PubMed  CAS  Google Scholar 

  • Flisiak R, Feinman SV, Jablkowski M, Horban A, Kryczka W, Pawlowska M, Heathcote JE, Mazzella G, Vandelli C, Nicolas-Metral V, Grosgurin P, Liz JS, Scalfaro P, Porchet H, Crabbe R (2009) The cyclophilin inhibitor Debio 025 combined with PEG IFnalpha2a significantly reduces viral load in treatment-naive hepatitis c patients. Hepatology (Baltimore, Md.) 49(5), 1460–1468

    Google Scholar 

  • Forns X, Bukh J (1999) The molecular biology of hepatitis c virus. Genotypes and quasispecies. Clinics in liver disease 3(4), 693–716, vii

    Google Scholar 

  • Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis c virus infection. The New England J Med 347(13):975–982

    Article  CAS  Google Scholar 

  • Gane EJ, Roberts SK, Stedman CAM, Angus PW, Ritchie B, Elston R, Ipe D, Morcos PN, Baher L, Najera I, Chu T, Lopatin U, Berrey MM, Bradford W, Laughlin M, Shulman NS, Smith PF (2010) Oral combination therapy with a nucleoside polymerase inhibitor (rg7128) and danoprevir for chronic hepatitis c genotype 1 infection (inform-1): a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 376(9751):1467–1475

    Article  PubMed  CAS  Google Scholar 

  • Gane EJ, Rouzier R, Stedman C, Wiercinska-Drapalo A, Horban A, Chang L, Zhang Y, Sampeur P, Najera I, Smith P, Shulman NS, Tran JQ (2011a) Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus peg-IFN alpha-2a/RBV in hepatitis c patients. J Hepatol 55(5):972–979

    Article  PubMed  CAS  Google Scholar 

  • Gane EJ, Stedman CA, Hyland RH, Sorensen RD, Symonds WT, Hindes R, Berrey MM (2011b) Once daily psi-7977 plus RBV: Pegylated interferon-alfa not required for complete rapid viral response in treatment-naive patients with HCV GT2 or GT3. Hepatology, 54(377A–377A)

    Google Scholar 

  • Gao M, Nettles RE, Belema M, Snyder LB, Nguyen VN, Fridell RA, Serrano-Wu MH, Langley DR, Sun J-H, O’boyle DR 2nd, Lemm JA, Wang C, Knipe JO, Chien C, Colonno RJ, Grasela DM, Meanwell NA, Hamann LG (2010) Chemical genetics strategy identifies an HCV NS5a inhibitor with a potent clinical effect. Nature 465(7294):96–100

    Article  PubMed  CAS  Google Scholar 

  • Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, Mchutchison JG, Goldstein DB (2009) Genetic variation in IL28b predicts hepatitis c treatment-induced viral clearance. Nature 461(7262):399–401

    Article  PubMed  CAS  Google Scholar 

  • Hadziyannis SJ, Sette H, Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H, Jr, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM & Group, P. I. S. (2004) Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis c: A randomized study of treatment duration and ribavirin dose. Anna Intern Med 140(5), 346–55

    Google Scholar 

  • Hagan H, Pouget ER, Des Jarlais DC (2011) A systematic review and meta-analysis of interventions to prevent hepatitis c virus infection in people who inject drugs. J Infect Dis 204(1):74–83

    Article  PubMed  Google Scholar 

  • Halfon P, Locarnini S (2011) Hepatitis c virus resistance to protease inhibitors. J Hepatol 55(1):192–206

    Article  PubMed  CAS  Google Scholar 

  • Hanoulle X, Badillo A, Wieruszeski J-M, Verdegem D, Landrieu I, Bartenschlager R, Penin F, Lippens G (2009) Hepatitis c virus NS5a protein is a substrate for the peptidyl-prolyl cis/trans isomerase activity of cyclophilins a and b. J Biol Chem 284(20):13589–13601

    Article  PubMed  CAS  Google Scholar 

  • Hayashi J, Aoki H, Kajino K, Moriyama M, Arakawa Y, Hino O (2000) Hepatitis C virus core protein activates the MAPK/ERK cascade synergistically with tumor promoter TPA, but not with epidermal growth factor or transforming growth factor alpha. Hepatology (Baltimore, Md.) 32(5), 958–961

    Google Scholar 

  • Hino O, Kajino K, Umeda T, Arakawa Y (2002) Understanding the hypercarcinogenic state in chronic hepatitis: a clue to the prevention of human hepatocellular carcinoma. J Gastroenterol 37(11):883–887

    Article  PubMed  CAS  Google Scholar 

  • Ishikawa T, Higuchi K, Kubota T, Seki K-I, Honma T, Yoshida T, Kamimura T (2012) Combination peg-IFN a-2b/ribavirin therapy following treatment of hepatitis c virus-associated hepatocellular carcinoma is capable of improving hepatic functional reserve and survival. Hepatogastroenterology 59(114):529–532

    PubMed  CAS  Google Scholar 

  • Jacobson IM, Mchutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S, Team AS (2011) Telaprevir for previously untreated chronic hepatitis c virus infection. The New England J Med 364(25):2405–2416

    Article  CAS  Google Scholar 

  • Kamal SM, Nasser IA (2008) Hepatitis c genotype 4: What we know and what we don’t yet know. Hepatology (Baltimore, Md.), 47(4), 1371–1383

    Google Scholar 

  • Khuroo MS, Khuroo MS, Dahab ST (2004) Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis c genotype 4. Aliment Pharmacol Ther 20(9):931–938

    Article  PubMed  CAS  Google Scholar 

  • Kisseleva T, Bhattacharya S, Braunstein J, Schindler CW (2002) Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene 285(1–2):1–24

    Article  PubMed  CAS  Google Scholar 

  • Kiyosawa K, Akahane Y, Nagata A, Furuta S (1984) Hepatocellular carcinoma after non-a, non-b posttransfusion hepatitis. Am J Gastroenterology 79(10):777–781

    CAS  Google Scholar 

  • Kohli V, Singhal A, Elliott L, Jalil S (2012) Antiviral therapy for recurrent hepatitis c reduces recurrence of hepatocellular carcinoma following liver transplantation. Transplant Int: official Journal of the European Society for Organ Transplantation 25(2):192–200

    Article  CAS  Google Scholar 

  • Kwo PY, Lawitz EJ, Mccone J, Schiff ER, Vierling JM, Pound D, Davis MN, Galati JS, Gordon SC, Ravendhran N, Rossaro L, Anderson FH, Jacobson IM, Rubin R, Koury K, Pedicone LD, Brass CA, Chaudhri E, Albrecht JK (2010) Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis c infection (sprint-1): an open-label, randomised, multicentre phase 2 trial. Lancet 376(9742):705–716

    Article  PubMed  CAS  Google Scholar 

  • Lagace L, Cartier M, Laflamme G, Lawetz C, Marquis M, Triki I, Bernard M-J, Bethell R, Larrey DG, Lueth S, Trepo C, Stern JO, Boecher WO, Steffgen J, Kukolj G (2010) Genotypic and phenotypic analysis of the NS5b polymerase region from viral isolates of HCV chronically infected patients treated with bi 207127 for 5-days monotherapy. Hepatology 52(4):1205A–1206A

    Google Scholar 

  • Lalezari J, Lawitz E, Rodriguez-Torres M, Sheikh A, Freilich B, Nelson DR, Hassanein T, Mader M, Albanis E, Symonds W, Berrey MM (2011) Once daily psi-7977 plus pegIFN/RBV in a phase 2b trial: Rapid virologic suppression in treatment-naive patients with HCV GT2/GT3. J Hepatol 54(S28–S28)

    Google Scholar 

  • Lauer GM, Barnes E, Lucas M, Timm J, Ouchi K, Kim AY, Day CL, Robbins GK, Casson DR, Reiser M, Dusheiko G, Allen TM, Chung RT, Walker BD, Klenerman P (2004) High resolution analysis of cellular immune responses in resolved and persistent hepatitis c virus infection. Gastroenterology 127(3):924–936

    Article  PubMed  CAS  Google Scholar 

  • Law MG, Dore GJ, Bath N, Thompson S, Crofts N, Dolan K, Giles W, Gow P, Kaldor J, Loveday S, Powell E, Spencer J, Wodak A (2003) Modelling hepatitis c virus incidence, prevalence and long-term sequelae in Australia. Int J Epidemiol 32(5):717–724

    Article  PubMed  Google Scholar 

  • Li X, Hui A-M, Sun L, Hasegawa K, Torzilli G, Minagawa M, Takayama T, Makuuchi M (2004) P16INK4a hypermethylation is associated with hepatitis virus infection, age, and gender in hepatocellular carcinoma. Clinical Cancer Res: Official J Am Assoc Cancer Res 10(22):7484–7489

    Article  CAS  Google Scholar 

  • Lok AS, Everhart JE, Wright EC, Di Bisceglie AM, Kim H.-Y, Sterling RK, Everson GT, Lindsay KL, Lee WM, Bonkovsky H. L, Dienstag JL, Ghany MG, Morishima C, Morgan TR & Group H.-C. T (2011) Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis c. Gastroenterology, 140(3), 840–849; quiz e12

    Google Scholar 

  • Lok AS, Seeff LB, Morgan TR, Di Bisceglie AM, Sterling RK, Curto TM, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Goodman Z D & Group, H.-C. T. (2009) Incidence of hepatocellular carcinoma and associated risk factors in hepatitis c-related advanced liver disease. Gastroenterology, 136(1), 138–148

    Google Scholar 

  • Manns MP, Mchutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling MH, Albrecht JK, & Int Hepatitis Interventional, T (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis c: A randomised trial. Lancet, 358(9286), 958–965

    Google Scholar 

  • Marcellin P, Boyer N, Gervais A, Martinot M, Pouteau M, Castelnau C, Kilani A, Areias J, Auperin A, Benhamou JP, Degott C, Erlinger S (1997) Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis c and sustained response to interferon-alpha therapy. Ann Intern Med 127(10):875–881

    Article  PubMed  CAS  Google Scholar 

  • Maruoka D, Imazeki F, Arai M, Kanda T, Fujiwara K, Yokosuka O (2012) Long-term cohort study of chronic hepatitis c according to interferon efficacy. J Gastroenterol Hepatol 27(2):291–299

    Article  PubMed  CAS  Google Scholar 

  • Mchutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, Mcnair L, Alam J, Muir AJ (2009a) Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection (vol 360, pg 1827, 2009). New England J Med 361(15), 1516–1516

    Google Scholar 

  • Mchutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, Mccone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS, Team IS (2009b) Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis c infection. The New England J Med 361(6):580–593

    Article  CAS  Google Scholar 

  • Mendenhall CL, Seeff L, Diehl AM, Ghosn SJ, French S W, Gartside PS, Rouster SD, Buskell-Bales Z, Grossman CJ, Roselle GA (1991) Antibodies to hepatitis b virus and hepatitis c virus in alcoholic hepatitis and cirrhosis: Their prevalence and clinical relevance. The VA cooperative study group (no. 119). Hepatology (Baltimore, Md.) 14(4 Pt 1), 581–589

    Google Scholar 

  • Nelson DR, Lalezari J, Lawitz E, Hassanein T, Kowdley K, Poordad F, Sheikh A, Afdhal N, Bernstein D, Dejesus E, Freilich B, Dieterich D, Jacobson I, Jensen D, Abrams GA, Darling J, Rodriguez-Torres M, Reddy R, Sulkowski M, Bzowej N, Demicco M, Strohecker J, Hyland R, Mader M, Albanis E, Symonds WT, Berrey MM (2011) Once daily psi-7977 plus peg-IFN/RBV in HCV GT1: 98% rapid virologic response, complete early virologic response: The proton study. J Hepatology, 54(S544-S544)

    Google Scholar 

  • Parkin DM (2001) Global cancer statistics in the year. Lancet Oncol 2(9):533–543

    Article  PubMed  CAS  Google Scholar 

  • Patel K, Muir AJ, Mchutchison JG (2006) Diagnosis and treatment of chronic hepatitis c infection. BMJ (Clinical research ed.) 332(7548):1013–1017

    Article  Google Scholar 

  • Patterson JL, Fernandezlarsson R (1990) Molecular mechanisms of action of ribavirin. Rev Infect Dis 12(6):1139–1146

    Article  PubMed  CAS  Google Scholar 

  • Pestka JM, Zeisel MB, Blaser E, Schurmann P, Bartosch B, Cosset F.-L, Patel AH, Meisel H, Baumert J, Viazov S, Rispeter K, Blum HE, Roggendorf M, Baumert TF (2007) Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Nat Acad Sci United States Am 104(14), 6025–6030

    Google Scholar 

  • Pockros P, Jensen D, Tsai N, Taylor RM, Ramji A, Cooper C, Dickson R, Tice A, Stancic S, Ipe D, Thommes JA, Vierling JM (2011) First svr data with the nucleoside analogue polymerase inhibitor mericitabine (rg7128) combined with peginterferon/ribavirin in treatment-naive HCV G1/4 patients: Interim analysis from the jump-c trial. J Hepatology, 54(S538–S538)

    Google Scholar 

  • Pol S, Ghalib RH, Rustgi V, Martorell C, Everson G, Tatum H, Hezode C, Lim J, Bronowicki J.-P, Abrams G, Brau N, Morris D, Thuluvath P, Reindollar R, Yin P, Diva U, Hindes R, Mcphee F, Gao M, Thiry A, Schnittman S, Hughes E (2011) First report of SVR12 for a NS5a replication complex inhibitor, BMS-790052 in combination with peg-IFN-alfa-2a and RBV: Phase 2a trial in treatment-naive HCV-genotype 1 subjects. 46th annual meeting of the European association for the study of the liver (easl 2011). J Hepatol 54, Suppl. 1 (S544–S545)

    Google Scholar 

  • Poordad F, Mccone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, Dinubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki J-P, Investigators S (2011) Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364(13):1195–1206

    Article  PubMed  CAS  Google Scholar 

  • Poynard T, Bedossa P, Opolon P (1997) Natural history of liver fibrosis progression in patients with chronic hepatitis c. The obsvirc, metavir, clinivir, and dosvirc groups. Lancet 349(9055):825–832

    Article  PubMed  CAS  Google Scholar 

  • Pradat P, Tillmann HL, Sauleda S, Braconier JH, Saracco G, Thursz M, Goldin R, Winkler R, Alberti A, Esteban JI, Hadziyannis S, Rizzetto M, Thomas H, Manns MP, Trepo C, Grp H (2007) Long-term follow-up of the hepatitis C HENCORE cohort: Response to therapy and occurrence of liver-related complications. J Viral Hepatitis 14(8):556–563

    Article  CAS  Google Scholar 

  • Raimondi S, Bruno S, Mondelli MU, Maisonneuve P (2009) Hepatitis c virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. J Hepatol 50(6):1142–1154

    Article  PubMed  CAS  Google Scholar 

  • Razali K, Thein HH, Bell J, Cooper-Stanbury M, Dolan K, Dore G, George J, Kaldor J, Karvelas M, Li J, Maher L, Mcgregor S, Hellard M, Poeder F, Quaine J, Stewart K, Tyrrell H, Weltman M, Westcott O, Wodak A, Law M (2007) Modelling the hepatitis c virus epidemic in Australia. Drug Alcohol Depend 91(2–3):228–235

    Article  PubMed  Google Scholar 

  • Romero-Gomez M, Del Mar Viloria M, Andrade RJ, Salmeron J, Diago M, Fernandez-Rodriguez CM, Corpas R, Cruz M, Grande L, Vazquez L, Munoz-De-Rueda P, Lopez-Serrano P, Gila A, Gutierrez ML, Perez C, Ruiz-Extremera A, Suarez E, Castillo J (2005) Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis c patients. Gastroenterology 128(3):636–641

    Article  PubMed  CAS  Google Scholar 

  • Serfaty L, Aumaitre H, Chazouilleres O, Bonnand AM, Rosmorduc O, Poupon RE, Poupon R (1998) Determinants of outcome of compensated hepatitis c virus-related cirrhosis. Hepatology (Baltimore, Md.) 27(5), 1435–1440

    Google Scholar 

  • Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N., Feinstone S, Halfon P, Inchauspe G, Kuiken C, Maertens G, Mizokami M, Murphy DG, Okamoto H, Pawlotsky J.-M, Penin F, Sablon E, Shin-I T, Stuyver LJ, Thiel H.-J, Viazov S, Weiner AJ, Widell A (2005) Consensus proposals for a unified system of nomenclature of hepatitis c virus genotypes. Hepatology (Baltimore, Md.) 42(4), 962–973

    Google Scholar 

  • Singal AK, Freeman DH Jr, Anand BS (2010a) Meta-analysis: Interferon improves outcomes following ablation or resection of hepatocellular carcinoma. Aliment Pharmacol Ther 32(7):851–858

    Article  PubMed  CAS  Google Scholar 

  • Singal AK, Singh A, Jaganmohan S, Guturu P, Mummadi R, Kuo Y-F, Sood GK (2010b) Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis c virus-related cirrhosis. Clinical Gastroenterology Hepatology:Official Clinical Prac J Am Gastroenterological Assoc 8(2):192–199

    Article  Google Scholar 

  • Sommereyns C, Paul S, Staeheli P, Michiels T (2008) IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 4(3):e1000017

    Article  PubMed  Google Scholar 

  • Streeter DG, Witkowsk Jt, Khare GP, Sidwell RW, Bauer R J, Robins RK, Simon LN (1973) Mechanism of action of 1-beta-d-ribofuranosyl-1,2,4-triazole-3-carboxamide (virazole)—new broad-spectrum antiviral agent. Proc Nat Acad Sci United States Am 70(4), 1174–1178

    Google Scholar 

  • Sun C-A, Wu D-M, Lin C–C, Lu S-N, You S-L, Wang L-Y, Wu M-H, Chen C-J (2003) Incidence and cofactors of hepatitis c virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan. Am J Epidemiol 157(8):674–682

    Article  PubMed  Google Scholar 

  • Takeyasu M, Akuta N, Suzuki F, Seko Y, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H (2012) Long-term interferon monotherapy reduces the risk of HCV-associated hepatocellular carcinoma. J Med Virol 84(8):1199–1207

    Article  PubMed  CAS  Google Scholar 

  • Thomas H, Foster G, Platis D (2003) Mechanisms of action of interferon and nucleoside analogues. J Hepatology, 39 Suppl 1(S93-8)

    Google Scholar 

  • Thomas MB, Zhu AX (2005) Hepatocellular carcinoma: the need for progress. J Clinical Oncology: Official J Am Society Clinical Oncology 23(13):2892–2899

    Article  Google Scholar 

  • Torresi J, Johnson D, Wedemeyer H (2011) Progress in the development of preventive and therapeutic vaccines for hepatitis c virus. J Hepatol 54(6):1273–1285

    Article  PubMed  CAS  Google Scholar 

  • Vajdy M, Selby M, Medina-Selby A, Coit D, Hall J, Tandeske L, Chien D, Hu C, Rosa D, Singh M, Kazzaz J, Nguyen S, Coates S, Ng P, Abrignani S, Lin Y-L, Houghton M, O’hagan DT (2006) Hepatitis c virus polyprotein vaccine formulations capable of inducing broad antibody and cellular immune responses. J Gen Virol 87(Pt 8):2253–2262

    Article  PubMed  CAS  Google Scholar 

  • Wang P, Heitman J (2005) The cyclophilins. Genome Biol 6(7):226

    Article  PubMed  Google Scholar 

  • Wiley TE, Mccarthy M, Breidi L, Layden TJ (1998) Impact of alcohol on the histological and clinical progression of hepatitis c infection. Hepatology (Baltimore, Md.) 28(3), 805–9

    Google Scholar 

  • Yu J-W, Wang G-Q, Sun L-J, Li X-G, Li S-C (2007) Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin. J Gastroenterol Hepatol 22(6):832–836

    Article  PubMed  CAS  Google Scholar 

  • Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Muellhaupt B, Pockros P, Terg R, Shouval D, Van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M, Team RS (2011a) Telaprevir for retreatment of HCV infection. N Engl J Med 364(25):2417–2428

    Article  PubMed  CAS  Google Scholar 

  • Zeuzem S, Arora S, Bacon B, Box T, Charlton M, Diago M, Dieterich D, Esteban Mur R, Everson GT, Fallón M, Ferenci P, Flisiak R, George J, Ghalib R, Gitlin N, Gladysz A, Gordon S, Greenbloom S, Hassanein T, Jacobson I, Jeffers L, Kowdley K, Lawitz E, Lee S, Leggett B, Lueth S, Nelson D, Pockros P, Rodriguez-Torres M, Rustgi V, Serfaty L, Sherman M, Shiffman M, Sola R, Sulkowski M, Vargas H, Vierling J, Yoffe B, Ishak L, Fontana D, Xu D, Lester J, Gray T, Horga A, Hillson J, Ramos E, Lopez-Talavera JC, Muir A (2011b) Pegylated interferon-lambda (pegIFN-l) shows superior viral response with improved safety and tolerability versus pegIFNa-2a in HCV patients (G1/2/3/4): Emerge phase IIb through week 12. J Hepatol, 54 Suppl. 1(S538–S539)

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Infectious Diseases, Austin Hospital, Heidelberg, Victoria, 3084, Australia

    J. Torresi

  2. Department of Gastroenterology, Austin Hospital, Heidelberg, Victoria, 3084, Australia

    E. J. Lim

Authors
  1. E. J. Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Torresi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. J. Lim .

Editor information

Editors and Affiliations

  1. Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan

    Mei Hwei Chang

  2. Molecular Virology Section, Lab. of Mole, National Institute of Allergy and Infect, Bethesda, Maryland, USA

    Kuan-Teh Jeang

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Lim, E.J., Torresi, J. (2014). Prevention of Hepatitis C Virus Infection and Liver Cancer. In: Chang, M., Jeang, KT. (eds) Viruses and Human Cancer. Recent Results in Cancer Research, vol 193. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-38965-8_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-38965-8_7

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-38964-1

  • Online ISBN: 978-3-642-38965-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation